Digoxin effect in mortality associated to right ventricular dysfunction in patients with pulmonary hypertension

H. Saucedo (Mexico City, Mexico), N. Zayas-Hernandez (Mexico City, Mexico), J. López-Flores (Mexico City, Mexico), T. Pulido-Zamudio (Mexico City, Mexico)

Source: International Congress 2019 – Pulmonary hypertension: clinical
Session: Pulmonary hypertension: clinical
Session type: Thematic Poster
Number: 4751
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Saucedo (Mexico City, Mexico), N. Zayas-Hernandez (Mexico City, Mexico), J. López-Flores (Mexico City, Mexico), T. Pulido-Zamudio (Mexico City, Mexico). Digoxin effect in mortality associated to right ventricular dysfunction in patients with pulmonary hypertension. 4751

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The evaluation of right and left ventricular dysfunction in COPD patients with pulmonary hypertension
Source: Eur Respir J 2001; 18: Suppl. 33, 250s
Year: 2001

Pulmonary hypertension, right and left ventricular dysfunction in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 404s
Year: 2006

Relation between hemodynamics and right ventricular hypertrophy may affect survival and severity of the disease in patients with primary pulmonary hypertension (PPH)
Source: Eur Respir J 2002; 20: Suppl. 38, 26s
Year: 2002

Pulmonary hypertension and right ventricular impairment in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 59s
Year: 2004

Prevalence of pulmonary hypertension and right ventricular dysfunction in patients with mixed types of ILD
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011


Risk factors for mortality in right ventricular failure and pulmonary arterial hypertension
Source: International Congress 2019 – COPD and other specific entities in intensive care unit medicine
Year: 2019


Τhe influence of pulmonary disease on ventricular diastolic dysfunction in COPD patients
Source: Eur Respir J 2003; 22: Suppl. 45, 539s
Year: 2003

Macitentan in pulmonary hypertension due to left ventricular dysfunction
Source: Eur Respir J, 51 (2) 1701886; 10.1183/13993003.01886-2017
Year: 2018



Pulmonary hypertension and right ventricular impairment in patients with sarcoidosis
Source: Annual Congress 2011 - Different profiles of sarcoidosis and other granulomatous disorders
Year: 2011

Improved right ventricular function after substantial afterload reduction in patients with pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment
Year: 2012

Pulmonary hypertension and right ventricular impairment in patients with interstitial pneumonia
Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases
Year: 2011

Prediction of right ventricular dysfunction in patients with pulmonary embolism
Source: Eur Respir J 2007; 30: Suppl. 51, 602s
Year: 2007

Right and left ventricular dysfunction in patients with COPD and heart failure
Source: Eur Respir J 2007; 30: Suppl. 51, 706s
Year: 2007

Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015


Right ventricular dysfunction in patients with pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005

Right ventricular function is a strong prognostic predictor of mortality in pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009


Left ventricular diastolic function in patients with high altitude-induced pulmonary hypertension
Source: Eur Respir J 2002; 20: Suppl. 38, 98s
Year: 2002

In patients with intermediate-low risk pulmonary embolism: cardiac enzyme or right ventricle dysfunction or sPESI
Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism
Year: 2017

CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension
Source: Eur Respir J, 57 (4) 1901192; 10.1183/13993003.01192-2019
Year: 2021



Spontaneous haemodynamic variability during right heart catetherisation in patients with pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary vascular diseases
Year: 2010